Mexico

The US administration added another layer of confusion after its overnight pronouncements on Mexican tariffs. For medtech, the uncertainty remains, and while the potential impact on the industry might still seem to be a simple question of bilateral trade math, which in itself is huge, the ramifications go even deeper – and wider, writes Bernard Murphy.

The president says 4 March would mark the start of tariffs he initially intended to take effect on 1 February before allowing a delay for Mexico and Canada to implement border security to help curb illegal entry by immigrants and fentanyl smuggling.

Lupin has added two ADHD drugs to its Canadian portfolio, while also signing multiple branded deals in other global markets.

Doubling down on its Latin American strategy, Zydus has managed to snap up a second biosimilar approval in Mexico, paving the way for future launches.

Marketed as Bhava, Zydus’ bevacizumab rival to Roche’s Avastin begins the firm’s biosimilar journey in the Latin American country.

The deal comes at a time when Latin American countries are increasingly looking to improve the regulatory environment for pharmaceuticals and move towards greater convergence.

Biocon Limited has struck a “semi-exclusive” distribution and supply deal with Mexican player Medix for local rights to the Indian firm’s liraglutide generic rival to Saxenda.

Direct seller reports Q1 sales up 1% to $1.3bn but net sales off 17.1% from year-ago period to $24.3m. Its distributor ranks jumped so far in 2024, particularly in China, where changes were made in the past year including new company leadership.

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.